guest ::
| Home > Publications database > ESTRO/ESGO/SIOPe guidelines for the management of patients with vaginal cancer. |
| Home > Publications database > ESTRO/ESGO/SIOPe guidelines for the management of patients with vaginal cancer. |
| Journal Article | DKFZ-2023-01694 |
; ; ; ; ; ; ; ; ; ; ; ; ; ;
2023
Elsevier Science
Amsterdam [u.a.]
This record in other databases: 
Please use a persistent id in citations: doi:10.1016/j.radonc.2023.109662
Abstract: Primary vaginal malignancies are rare, comprising only 2% of all female genital tract malignancies in adults and 4.5% in children. As part of its mission to improve the quality of care for women with gynecological cancers across Europe, the European Society of Gynaecological Oncology (ESGO) jointly with the European Society for Radiotherapy & Oncology (ESTRO) and the European Society of Pediatric Oncology (SIOPe) developed evidence-based guidelines in order to improve the management of patients with vaginal cancer within a multidisciplinary setting. ESTRO/ESGO/SIOPe nominated practicing clinicians who are involved in the management of vaginal cancer patients and have demonstrated leadership through their expertise in clinical care and research, their national and international engagement and profile as well as dedication to the topics addressed to serve on the expert panel (13 experts across Europe comprising the international development group). To ensure that the statements were evidence based, the current literature was reviewed and critically appraised. In the case of absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the international development group. Prior to publication, the guidelines were reviewed by 112 independent international practitionners in cancer care delivery and patient representatives and their comments and input were incorporated and addressed accordingly. These guidelines cover comprehensively the diagnostic pathways as well as the surgical, radiotherapeutical and systemic management and follow-up of adult patients (including those with rare histological subtypes) and pediatric patients (vaginal rhabdomyosarcoma and germ cell tumours) with vaginal tumours.
Keyword(s): Adult (MeSH) ; Female (MeSH) ; Humans (MeSH) ; Child (MeSH) ; Vaginal Neoplasms: radiotherapy (MeSH) ; Radiation Oncology (MeSH) ; Gynecology (MeSH) ; Medical Oncology (MeSH) ; Uterine Cervical Neoplasms: therapy (MeSH) ; Carcinoma in Situ (MeSH) ; Adolescent ; Adult ; Childhood ; Guidelines ; Management ; Vaginal cancer
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz
; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
